CN115925972A - 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法 - Google Patents

在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法 Download PDF

Info

Publication number
CN115925972A
CN115925972A CN202210858173.1A CN202210858173A CN115925972A CN 115925972 A CN115925972 A CN 115925972A CN 202210858173 A CN202210858173 A CN 202210858173A CN 115925972 A CN115925972 A CN 115925972A
Authority
CN
China
Prior art keywords
protein
toxin
conjugate
plant
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210858173.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·玛吉
M·乌里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atb Therapy
Original Assignee
Atb Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atb Therapy filed Critical Atb Therapy
Publication of CN115925972A publication Critical patent/CN115925972A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202210858173.1A 2019-02-18 2020-02-18 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法 Pending CN115925972A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19157839.2 2019-02-18
EP19157839 2019-02-18
CN202080029119.5A CN113728107B (zh) 2019-02-18 2020-02-18 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
PCT/EP2020/054263 WO2020169620A1 (en) 2019-02-18 2020-02-18 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080029119.5A Division CN113728107B (zh) 2019-02-18 2020-02-18 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法

Publications (1)

Publication Number Publication Date
CN115925972A true CN115925972A (zh) 2023-04-07

Family

ID=65717705

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210858173.1A Pending CN115925972A (zh) 2019-02-18 2020-02-18 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
CN202080029119.5A Active CN113728107B (zh) 2019-02-18 2020-02-18 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080029119.5A Active CN113728107B (zh) 2019-02-18 2020-02-18 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法

Country Status (11)

Country Link
US (1) US20220090113A1 (https=)
EP (2) EP4733324A2 (https=)
JP (2) JP7150999B2 (https=)
KR (1) KR102398485B1 (https=)
CN (2) CN115925972A (https=)
BR (1) BR112021016348A2 (https=)
CA (1) CA3128793C (https=)
ES (1) ES3055338T3 (https=)
IL (1) IL285719B (https=)
WO (1) WO2020169620A1 (https=)
ZA (1) ZA202105654B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925972A (zh) * 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
CN115768897B (zh) * 2020-05-28 2026-03-27 中外制药株式会社 改进的颗粒酶b变体
JP7818834B2 (ja) 2020-08-17 2026-02-24 エーティービー セラピューティクス リボトキシンまたはＲＮＡｓｅを含む組換え免疫毒素
EP4328243A4 (en) * 2021-04-20 2025-05-21 Korea University Research and Business Foundation Asymmetric antibody with improved cytotoxicity against cancer cell
IL314969A (en) 2022-02-17 2024-10-01 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN114605556B (zh) * 2022-03-10 2023-04-14 南开大学 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1555268A (zh) * 2001-07-17 2004-12-15 �������о�����չ˽�����޹�˾ 含促调亡蛋白质的治疗剂
CN102633880A (zh) * 2003-05-02 2012-08-15 赞科股份有限公司 优化的Fc变体及其产生方法
CN105753986A (zh) * 2016-04-24 2016-07-13 赵磊 一类抗cd20靶向抗体及用途技术领域
CN106397595A (zh) * 2008-05-02 2017-02-15 F-星生物技术研究与开发有限公司 细胞毒免疫球蛋白

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6140075A (en) 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2705289A1 (en) * 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
US20130145502A1 (en) 2010-06-09 2013-06-06 Pioneer Hi-Bred International, Inc. Regulatory sequences for modulating transgene expression in plants
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
WO2016187585A1 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN115925972A (zh) * 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1555268A (zh) * 2001-07-17 2004-12-15 �������о�����չ˽�����޹�˾ 含促调亡蛋白质的治疗剂
CN102633880A (zh) * 2003-05-02 2012-08-15 赞科股份有限公司 优化的Fc变体及其产生方法
CN106397595A (zh) * 2008-05-02 2017-02-15 F-星生物技术研究与开发有限公司 细胞毒免疫球蛋白
CN105753986A (zh) * 2016-04-24 2016-07-13 赵磊 一类抗cd20靶向抗体及用途技术领域

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOSEPH A. FRANCISCO ET AL.: "Expression and Characterization of Bryodin 1 and a Bryodin 1-Based Single-Chain Immunotoxin from Tobacco Cell Culture", BIOCONJUGATE CHEMISTRY, vol. 8, no. 5, 31 December 1997 (1997-12-31), pages 708 - 713, XP001222063, DOI: 10.1021/bc970107k *
MADHUMATHI J AND RAMA S VERMA: "Therapeutic targets and recent advances in protein immunotoxins", CURRENT OPINION IN MICROBIOLOGY, vol. 15, no. 3, 28 May 2012 (2012-05-28), pages 300 - 309, XP028449289, DOI: 10.1016/j.mib.2012.05.006 *
TAO WANG ET AL.: "Recombinant Immunoproapoptotic Proteins with Furin Site Can Translocate and Kill HER2-Positive Cancer Cells", CANCER RESEARCH, vol. 67, no. 24, 15 December 2007 (2007-12-15), pages 11830 - 11839, XP002792632, DOI: 10.1158/0008-5472.CAN-07-1160 *

Also Published As

Publication number Publication date
CA3128793C (en) 2023-02-28
EP3927831B1 (en) 2025-11-12
US20220090113A1 (en) 2022-03-24
KR102398485B1 (ko) 2022-05-16
ZA202105654B (en) 2023-04-26
BR112021016348A2 (pt) 2021-11-23
WO2020169620A1 (en) 2020-08-27
CA3128793A1 (en) 2020-08-27
EP3927831C0 (en) 2025-11-12
KR20210120051A (ko) 2021-10-06
ES3055338T3 (en) 2026-02-11
CN113728107B (zh) 2022-06-24
EP4733324A2 (en) 2026-04-29
JP2022176933A (ja) 2022-11-30
EP3927831A1 (en) 2021-12-29
JP2022518614A (ja) 2022-03-15
JP7728587B2 (ja) 2025-08-25
IL285719B (en) 2022-07-01
IL285719A (en) 2021-10-31
CN113728107A (zh) 2021-11-30
JP7150999B2 (ja) 2022-10-11

Similar Documents

Publication Publication Date Title
CN113728107B (zh) 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
Satheeshkumar Expression of single chain variable fragment (scFv) molecules in plants: A comprehensive update
Chen et al. Efficient production of a bioactive bevacizumab monoclonal antibody using the 2A self-cleavage peptide in transgenic rice callus
Stelter et al. Engineering the interactions between a plant‐produced HIV antibody and human Fc receptors
Phakham et al. Functional characterization of pembrolizumab produced in Nicotiana benthamiana using a rapid transient expression system
Marusic et al. Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells
Ehsani et al. Expression of anti human IL-4 and IL-6 scFvs in transgenic tobacco plants
JP7818834B2 (ja) リボトキシンまたはＲＮＡｓｅを含む組換え免疫毒素
US20090041776A1 (en) Production of cancer-specific antibodies in plants
US20250387478A1 (en) Recombinant immunotoxin comprising a ribosome inactivating protein
Kang et al. Comparison of CD20 binding affinities of rituximab produced in Nicotiana benthamiana leaves and Arabidopsis thaliana Callus
Zagorskaya et al. Recombinant monoclonal antibodies synthesized in plant expression systems: problems and prospects
CN101426814A (zh) 组合物和用于植物中n聚糖的人源化和最优化的方法
Lee et al. Plant-derived CD200-Fc promotes tight junction integrity in bladder epithelial cells
Dianatkhah et al. In planta transient recombinant production of a bispecific T-cell engager: Blinatumomab
Lonoce Production of tumour-targeting antibodies in hairy root cultures
Westerhof Plants as a production platform for high-value proteins
Lombardi Plant production of a tumour-targeting human IgG. Considerations on expression strategies, glycosylation profile and in planta proteolysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination